维普期刊资源整合服务平台（V6.5）

28篇 您的检索式：作者名="Schmith"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Pharmacokinetics of alvimopan and its metabolite in healthy volunteers and patients in postoperative ileus trials 显示文摘	Foss JF Fisher DM Schmith VD	2008	Clin Pharmacol Ther2008，83，5：	1
2	Damage, connectivity and essentiality in protein–protein interaction networks显示文摘	Jean Schmith Ney Lemke José C.M. Mombach Patrícia Benelli Cláudia K. Barcellos Guilherme B. Bedin	2004	Physica A: Statistical Mechanics and its Applications2004，，3：	1
3	Pharmacogenetics and Disease Genetics of Complex Diseases显示文摘	Schmith VD Campbell DA Sehgal S	2003	Cell Mol Life Sci2003，60，8：	1
4	Clinical pharmacokinetics of cisatracurium besilate显示文摘	KISOR DF SCHMITH VD	1999	Clinical Pharmacokinetics1999，36，1：	1
5	Alvimopan (Entereg) , a novel opioid antagonist, achieves active systemic concentrations显示文摘	FOSS J SCHMITH V WALLIN B	2005	Clin Pharmacol Ther2005，77，：	1
6	Effect of elemental sulfur on corrosion in sour gas systems 显示文摘	SCHMITH G	1991	Corrosion1991，47，4：	1
7	Organ-nonde-pendentpathway of the neuromuscular blocking agent 51W89 in man显示文摘	Kisor D F Wargin W A Schmith V D	1994	Pharm Re1994，11，：	1
8	Organ - nondependent Hofmannelimination is the major clearance pathway of the neuromuscular blocking agent 51W89 in man 显示文摘	Kisor DF Wargin WA Schmith VD	1994	Pharm Re1994，11，：	1
9	Organ-nondependent Hoffmann elimination is the major clearance pathway of the neuromuscular blocking agent显示文摘	Kisor DF Wargin WA Schmith VD	1994	Pharm Res1994，11，：	1
10	Pharmacogenetics and Disease Genetics of Complex Diseases显示文摘	Schmith VD Campbell DA Sehgal S	2003	Cell Mol Life Sci2003，60，8：	1
11	Prospective use of population pharmacokinetics/pharmacodynamics in the devel- opment of cisatracurium 显示文摘	Schmith V D Fiedler-Kelly J Phillips L	1997	Pharm Res1997，14，：	1
12	Clinical Pharmacokinetics of Cisatracurium Besilate显示文摘	Kisor DF Schmith VD	1999	Clin Pharmacokinet1999，36，1：	1
13	Importance of the organ- ind ependent elimination of cisatracurium显示文摘	Kisor DF Schmith VD Wargin WA	1996	Anesth-Analg1996，83，5：	1
14	Prospective use of population pharmackinetics/pharmacodynamics in the development of cisatracurium显示文摘	Schmith VD Fiedler-Kelly J Phillips L	1997	Phann Res1997，14，1：	1
15	Importance of the organ-independent elimination of cisatracurium显示文摘	Kisor DF Schmith VD Wargin WA	1996	Anesthesia & Analgesia1996，83，5：	1
16	Prospective use of population pharmacokinetics/ pharmacodynamics in the development of eisatraeurium显示文摘	SCHMITH V D FIEDLER-KELLY J PHILLIPS L	1997	Pharm Res1997，14，1：	1
17	Organ-nondependent Hoffmann elimination is the major clearance pathway of the neuromuscular blocking agent 51W89 in man 显示文摘	Kisor DF Wargin WA Schmith VD	1994	Pharm Re1994，11，：	1
18	The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in pa- tients receiving nitrous oxide/opioid/barbiturate anesthesia显示文摘	Lien CA Schmith VD Ernbree PB	1994	Anesthesiology1994，80，6：	1
19	Pharmacogenetics and disease genetics of complex diseases显示文摘	Campbell DA Sehgal S	2003	Cell Mol Life Sci2003，60，8：	1
20	Importance of the organ-independent elimination of cisatracurium显示文摘	Kisor D F Schmith V D Wargin W A	1996	Anesth Analg1996，83，5：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示